To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Dear Sir/Madam,

Sub: Alembic Pharmaceuticals announces its joint venture, Aleor Dermaceuticals Limited, receives USFDA Tentative Approval for Tavaborole Topical Solution, 5%.

With reference to the captioned subject, this is to inform the exchange that the Company’s joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Tentative Approval for Tavaborole Topical Solution, 5%.

Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja
Company Secretary

Encl.: A/a.
PRESS RELEASE

13th August, 2020, Vadodara, India

Alembic Pharmaceuticals announces its joint venture, Aleor Dermaceuticals receives USFDA Tentative Approval for Tavaborole Topical Solution, 5%.

Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tavaborole Topical Solution, 5%. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Kerydin Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. (Anacor). Tavaborole topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

Tavaborole Topical Solution, 5% has an estimated market size of US$ 82 million for twelve months ending June 2020 according to IQVIA. Alembic is currently in litigation with Anacor in District Court of Delaware and launch of the product will depend on litigation outcome.

Alembic has a cumulative total of 128 ANDA approvals (112 final approvals and 16 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at http://www.alembicpharmaceuticals.com/; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573).

About Aleor Dermaceuticals Limited

Aleor is a 60:40 joint venture between Alembic and Orbicular Pharmaceutical Technologies Pvt Ltd (Orbicular) formed in Apr’16 focusing on commercialising dermatology products globally.

For more information contact:

<table>
<thead>
<tr>
<th>Name</th>
<th>Phone Number</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ajay Kumar Desai</td>
<td>+91 22 - 306 11681</td>
<td><a href="mailto:ajay.desai@alembic.co.in">ajay.desai@alembic.co.in</a></td>
</tr>
<tr>
<td>Mitanshu Shah</td>
<td>+91 265 - 3007630</td>
<td><a href="mailto:mitanshu.shah@alembic.co.in">mitanshu.shah@alembic.co.in</a></td>
</tr>
</tbody>
</table>